Pharmacokinetics of ecteinascidin 743 administered as a 24-h continuous intravenous infusion to adult patients with soft tissue sarcomas: Associations with clinical characteristics, pathophysiological variables and toxicity

Cancer Chemotherapy and Pharmacology

Volumn 50, Issue 4, 2002, Pages 309-319

  Puchalski, Thomas A ^a   Ryan, David P ^a   Garcia Carbonero, Rocio ^a   Demetri, George D ^a   Butkiewicz, Leah ^a   Harmon, David ^a   Seiden, Michael V ^a   Maki, Robert G ^b   Lopez Lazaro, Luis ^c   Jimeno, Jose ^c   Guzman, Cecilia ^c   Supko, Jeffrey G ^a,d  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c PHARMAMAR S A   (Spain)

^d NONE   (United States)

Author keywords

Cancer; Chemotherapy; Clinical trials; Human; Phase II

Indexed keywords

ALKALINE PHOSPHATASE; DEXAMETHASONE; LIVER ENZYME; SEROTONIN ANTAGONIST; TRABECTEDIN;

ADULT; AGED; ANEMIA; AREA UNDER THE CURVE; ARTICLE; BODY SURFACE; BONE MARROW SUPPRESSION; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG METABOLISM; DYSPNEA; ENZYME BLOOD LEVEL; FATIGUE; FEMALE; GEOMETRY; HISTOPATHOLOGY; HUMAN; KIDNEY FUNCTION; LEUKOPENIA; LIVER FUNCTION TEST; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; PATHOPHYSIOLOGY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SOFT TISSUE SARCOMA; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADULT; ANTINEOPLASTIC AGENTS; DEXAMETHASONE; DIOXOLES; HUMANS; INFUSIONS, INTRAVENOUS; ISOQUINOLINES; LIVER FUNCTION TESTS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEUTROPENIA; SARCOMA; TETRAHYDROISOQUINOLINES; TRANSAMINASES;

EID: 0036387382     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-002-0498-3     Document Type: Article

References (31)

1. Delaloge S, Yovine A, Taamma A, Riofrio M, Brain E, Raymond E, Cottu P, Goldwasser F, Jimeno J, Misset JL, Marty M, Cvitkovic E (2001) Ecteinascidin-743: a marine-derived compound in advanced, pretreated sarcoma patients -preliminary evidence of activity. J Clin Oncol 19:1248
2. Donald S, Verschoyle R, Greaves P, Colombo T, Frapoli R, D'Incalci M, Lopez-Lazaro L, Gescher A (2001) Modulation of hepatotoxicity of ecteinascidin 743 (ET-743) in the rat. Clin Cancer Res 7(S):271
3. Forouzesh B, Hidalgo M, Denis L, Schwartz G, Hammond L, Monroe P, Guzman C, Lopez Lazaro L, Supko J, Jimeno J, Rowinsky E (2001) Phase I and pharmacokinetic study of ET-743, a minor groove DNA binder, administered weekly to patients with advanced cancer. Proc Am Soc Clin Oncol 20:373
4. Gómez J, Lázaro LL, Guzmán C, González A, Misset JL, Twelves C, Bowman A, Hoekman K, Villalona M, Ryan D, Paz-Ares, Jimeno J (2000) Identification of biochemical parameters that predict the onset of severe toxicities in patients treated with ET-743. Proc Am Soc Clin Oncol 19:187
5. Gurney H (1996) Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative. J Clin Oncol 14:2590
6. Hendriks HR, Fiebig HH, Giavazzi R, Langdon SP, Jimeno JM, Faircloth GT (1999) High antitumour activity of ET743 against human tumour xenografts from melanoma, non-small-cell lung and ovarian cancer. Ann Oncol 10:1233
7. Jimeno J, Faircloth G, Cameron L, Meely K, Vega E, Gomez A, Sousa-Faro JF, Rinehart K (1996) Progress in the acquisition of new marine-derived anticancer compounds: development of ecteinascidin-743 (ET-743). Drugs Future 21:1155
8. Jin S, Gorfajn B, Faircloth G, Scotto KW (2000) Ecteinascidin 743, a transcription-targeted chemotherapeutic that inhibits MDR1 activation. Proc Natl Acad Sci U S A 97:6775
9. Kristensen MB (1976) Drug interactions and clinical pharma-cokinetics. Clin Pharmacokinet 1:351
10. KuAel MJ, Reid JM, Ames MM (1997) Cytochrome P450 catalyzed metabolism of ecteinascidin 743 by rat and human liver microsomes. Proc Am Assoc Cancer Res 38:596
11. Lai AA, Levy RH, Cutler RE (1978) Time-course of interaction between carbamazepine and clonazepam in normal man. Clin Pharmacol Ther 24:316
12. Lam FC, Hung CT, Perrier DG (1985) Estimation of variance for harmonic mean half-lives. J Pharm Sci 74:229
13. Minuzzo M, Marchini S, Broggini M, Faircloth G, D'Incalci M, Mantovani R (2000) Interference of transcriptional activation by the antineoplastic drug ecteinascidin-743. Proc Natl Acad Sci U S A 97:6780
14. Mizuta E, Tsubotani A (1985) Preparation of mean drug concentration-time curves in plasma. A study on the frequency distribution of pharmacokinetic parameters. Chem Pharm Bull (Tokyo) 33:1620
15. Moore B, Seaman F, Hurley L (1997) NMR-based model of an ecteinascidin 743-DNA adduct. J Am Chem Soc 119:5475
16. Oinonen T, Lindros KO (1998) Zonation of hepatic cytochrome P-450 expression and regulation. Biochem J 329:17
17. Pommier Y, Kohlhagen G, Bailly C, Waring M, Mazumder A, Kohn KW (1996) DNA sequence- and structure-selective alkylation of guanine N2 in the DNA minor groove by ecteinascidin 743, a potent antitumor compound from the Caribbean tunicate Ecteinascidia turbinata. Biochemistry 35:13303
18. Reid JM, Kuffel MJ, Squillace DP, Ames MM (1998) Characterization of the in vitro metabolism, pharmacokinetics, and biliary excretion of ecteinascidin 743 (NSC 648766) in male and female rats. Ann Oncol 9 (S2):50
19. Rinehart K, Holt T, Fregeau N, Stroh J, Keifer P, Sun F, Li L, Martin D (1990) Ecteinascidins 729, 743, 745, 759A, 759B, and 770: potent antitumor agents from the Caribbean tunicate Ecteinascidia turbinata. J Org Chem 55:4512
20. Ryan DP, Supko JG, Eder JP, Seiden MV, Demetri G, Lynch TJ, Fischman AJ, Davis J, Jimeno J, Clark JW (2001) Phase I and pharmacokinetic study of ecteinascidin 743 administered as a 72-hour continuous intravenous infusion in patients with solid malignancies. Clin Cancer Res 7:231
21. Sawyer M, Ratain MJ (2001) Body surface area as a determinant of pharmacokinetics and drug dosing. Invest New Drugs 19(2):171
22. Schuetz EG, Guzelian PS (1984) Induction of cytochrome P-450 by glucocorticoids in rat liver. II. Evidence that glucocorticoids regulate induction of cytochrome P-450 by a nonclassical receptor mechanism. J Biol Chem 259:2007
23. Schuetz EG, Wrighton SA, Barwick JL, Guzelian PS (1984) Induction of cytochrome P-450 by glucocorticoids in rat liver. I. Evidence that glucocorticoids and pregnenolone 16 alpha-carbonitrile regulate de novo synthesis of a common form of cytochrome P-450 in cultures of adult rat hepatocytes and in the liver in vivo. J Biol Chem 259:1999
24. Sparidans RW, Rosing H, Hillebrand MJ, Lopez-Lazaro L, Jimeno JM, Manzanares I, van Kesteren C, Cvitkovic E, van Oosterom AT, Schellens JH, Beijnen JH (2001) Search for metabolites of ecteinascidin 743, a novel, marine-derived, anti-cancer agent, in man. Anticancer Drugs 12:653
25. Taamma A, Misset JL, Riofrio M, Guzman C, Brain E, Lopez Lazaro L, Rosing H, Jimeno JM, Cvitkovic E (2001) Phase I and pharmacokinetic study of ecteinascidin-743, a new marine compound, administered as a 24-hour continuous infusion in patients with solid tumors. J Clin Oncol 19:1256
26. Takebayashi Y, Pourquier P, Zimonjic DB, Nakayama K, Emmert S, Ueda T, Urasaki Y, Kanzaki A, Akiyama SI, Popescu N, Kraemer KH, Pommier Y (2001) Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair. Nat Med 7:961
27. Twelves CJ, Bowman A, Hoekman K, Simpson A, Smyth J, Vermoken J, Hoppener F, Beijnen J, Cameron L, Jimeno J, Hanauske AR (1998) Phase I clinical and pharmacokinetic study of ecteinascidin-743 given as a one hour infusion every 21 days. Proc Am Soc Clin Oncol 17:232
28. Twelves CJ, Hoeckman H, Bowman A, Beijnen JH, Faber M, Guzman C, Anthoney A, Smyth J, Hanauske AR, Jimeno J (1999) A phase I and pharmacokinetic study of ET-743 evaluating a 3 hours intravenous infusion in patients with solid tumors. Clin Cancer Res 5(S):3790
29. van Kesteren C, Cvitkovic E, Taamma A, Lopez-Lazaro L, Jimeno JM, Guzman C, Mathot RA, Schellens JH, Misset JL, Brain E, Hillebrand MJ, Rosing H, Beijnen JH (2000) Pharmacokinetics and pharmacodynamics of the novel marine-derived anticancer agent ecteinascidin 743 in a phase I dose-finding study. Clin Cancer Res 6:4725
30. Villalona-Calero MA, Eckhardt SG, Weiss G, Hidalgo M, Beijnen JH, van Kesteren C, Rosing H, Campbell E, Kraynak M, Lopez-Lazaro L, Guzman C, Von HoA DD, Jimeno J, Rowinsky EK (2002) A phase I and pharmacokinetic study of ecteinascidin 743 on a daily × 5 schedule in patients with solid malignancies. Clin Cancer Res 8:75
31. Yovine A, Riofrío M, Brain E, Blay JY, Kahatt C, Delaloge S, Beautier L, Cottu P, Jimeno J, Cvitkovic E, Misset JL, Brousse HP (2001) Ecteinascidin (ET-743) Given as a 24 hour (H) intravenous continuous infusion (IVCI) every 3 weeks: results of a phase II trial in patients (pts) with pretreated soft tissue sarcomas (PSTS). Proc Am Soc Clin Oncol 20:1449